Form 4: Gilead Sciences Director Ted W. Love Reports Acquisition of Stock and Stock Options

Director Ted W. Love reports acquisition of Gilead Sciences stock and stock options, including 1,516 restricted stock units and options to purchase 6,809 shares, all vesting immediately.

Summary

• On May 7, 2025, Ted W. Love, a director of Gilead Sciences, Inc., reported the acquisition of 1,516 shares of common stock through restricted stock units (RSUs) under the 2022 Equity Incentive Plan.
• These RSUs vested immediately upon the grant date.
• Love also acquired a non-qualified stock option to buy 6,809 shares of Gilead Sciences common stock at an exercise price of $98.90.
• This stock option also vested immediately upon the grant date and expires on May 7, 2035.
• Following these transactions, Love directly owns 6,809 derivative securities and 4,338 shares of Gilead Sciences common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction of stock and option grants to a company director. It doesn't inherently indicate positive or negative performance.

Positives

• The immediate vesting of both the RSUs and stock options suggests a strong incentive alignment between the director and the company's performance.

Future Outlook

There is no future outlook provided in this document.

Industry Context

This filing is a routine disclosure related to executive compensation and equity grants, common in the pharmaceutical industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Equity grants, including RSUs and stock options, are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Pfizer, and Johnson & Johnson also utilize similar equity-based compensation plans to align executive interests with shareholder value.
• The vesting schedules and grant sizes are typically benchmarked against peer companies to ensure competitiveness.

Stakeholder Impact

• The equity grants aim to align the director's interests with those of the shareholders, potentially driving long-term value creation.

Key Dates

Keywords

Gilead Sciences, Director, Ted W. Love, Stock Options, Restricted Stock Units, RSUs, Form 4, Beneficial Ownership, Equity Incentive Plan